title: Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
abstract: BACKGROUND
  The role of brentuximab peri-allogeneic transplantation in patients with relapsed and/or refractory CD30 positive lymphomas remains poorly defined.
  
  
  OBJECTIVE
  To assess the outcome of use of brentuximab as a bridge to allogeneic stem cell transplantation (SCT) in patient with relapsed/refractory CD30+ classic Hodgkin lymphoma cHL and anaplastic large cell lymphoma (ALCL).
  
  
  METHODS
  Outcomes of consecutive patients with relapsed/refractory cHL/ALCL treated with brentuximab as a bridge to SCT were determined by retrospective review of individual medical records. Survival analysis was measured from start of brentuximab treatment.
  
  
  RESULTS
  A total of 12 patients (10 cHL, 2 ALCL) had received brentuximab as a planned bridge to allogeneic SCT. Median age was 27 years (range 20-54 years); median prior lines of therapy was 4 (range 3-6) and all except one patient had undergone prior autologous SCT (92%). Patients received at median of 3 brentuximab doses pre-allogeneic SCT (range 1-4), with an overall response rate of 66.7%. At a median follow up of 30 months (range 6-52 months), 2 years progression free survival and overall survival post-allogeneic SCT is 58 and 92% respectively. Incidence of non-relapse mortality, grade 3-4 acute graft versus host disease and extensive stage chronic graft versus host disease is 8, 17 and 18% respectively. Of five patients who subsequently relapsed post-SCT, four remain alive with disease control post manipulation of immune-suppression.
  
  
  CONCLUSIONS
  Our experience suggests that brentuximab use pre-allogeneic SCT is not associated with any significant post-transplant toxicity, and is associated with a rapid response in a majority of patients with relapsed/refractory CD30 positive lymphomas. Brentuximab may thus provide a non-toxic bridge to allogeneic SCT for patients with relapsed/refractory CD30 positive cHL or ALCL.
authors.affiliation: Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.|School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Heshani
authors.identifier: http://orcid.org/0000-0002-4521-7970
authors.initials: H
authors.lastname: Mediwake
authors.affiliation: Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
authors.forename: Kirk
authors.initials: K
authors.lastname: Morris
authors.affiliation: Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
authors.forename: Cameron
authors.initials: C
authors.lastname: Curley
authors.affiliation: Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
authors.forename: Jason
authors.initials: J
authors.lastname: Butler
authors.affiliation: Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.|School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Glen
authors.initials: G
authors.lastname: Kennedy
mesh_terms: D000328:Adult; D000079963:Brentuximab Vedotin; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; allogeneic stem cell transplantation; anaplastic large cell lymphoma